Patents Examined by Dong Jiang
  • Patent number: 10131709
    Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: November 20, 2018
    Assignee: ImmunoQure AG
    Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa Macagno, Shimobi Onuoha
  • Patent number: 10087227
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: October 2, 2018
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang
  • Patent number: 10081676
    Abstract: Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: September 25, 2018
    Assignee: ImmunoQure AG
    Inventors: Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Shimobi Onuoha, Paert Peterson, Mike Rothe, Martin Woodward, Syeda F. Y. Haque
  • Patent number: 10077301
    Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-21 (IL-21) and uses thereof, e.g., in therapy.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: September 18, 2018
    Assignee: Monash University
    Inventors: Charles Reay Mackay, Di Yu
  • Patent number: 10072085
    Abstract: The present disclosure relates to ?M-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: September 11, 2018
    Assignee: Kirin-Amgen, Inc.
    Inventors: Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher Endres
  • Patent number: 10059753
    Abstract: The present invention provides a mutant chicken interleukin-1? protein as a chicken interleukin-1? antagonist, which has a substituted peptide at position 117 and/or 118 of wild-type chicken interleukin-1? peptides. The mutant chicken interleukin-1? protein is created by using point mutation in a method genetic engineering; it can significantly inhibit proliferation of avian virus, such as avian influenza virus, avian reovirus and Marek's disease virus, and avian inflammation response. Therefore, the mutant chicken interleukin-1? protein of the present invention can be used as antiviral and anti-inflammatory medication.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: August 28, 2018
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Hsien-Sheng Yin, Wen-Ting Chen
  • Patent number: 10059764
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: August 28, 2018
    Assignee: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
  • Patent number: 10028998
    Abstract: The present invention relates to a method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease in a patient, wherein the method comprises providing a pharmaceutical composition containing a therapeutically effective amount of soluble Fc?R; administering said composition to a patient, followed by a safety period of several weeks, followed by a subsequent treatment cycle of at least two weekly administrations, wherein said therapeutically effective amount is effective to treat or prevent said disease in said patient. The present invention also provides a pharmaceutical composition in the form of a multiple-dosage-kit which contains sufficient amounts of administration doses of soluble Fc?R for effectively treating or preventing inflammatory diseases and/or autoimmune diseases in a patient.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: July 24, 2018
    Assignee: SUPPREMOL GMBH
    Inventors: Peter Buckel, Peter Sondermann, Sascha Tillmanns, Ingrid Berger
  • Patent number: 10022443
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: July 17, 2018
    Assignee: Boston Pharmaceuticals Inc.
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
  • Patent number: 10023656
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: July 17, 2018
    Assignee: ZYMOGENETICS INC.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Patent number: 10017568
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: July 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • Patent number: 10011654
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: July 3, 2018
    Assignee: Genentech, Inc.
    Inventors: David P. Arnott, Austin L. Gurney, Philip E. Hass, James M. Lee, Yan Wu
  • Patent number: 9999666
    Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: June 19, 2018
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Hsiang-Chuan Hsieh
  • Patent number: 10000563
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: June 19, 2018
    Assignee: ZYMOGENETICS, INC.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • Patent number: 9994634
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: June 12, 2018
    Assignee: ZYMOGENETICS, INC.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • Patent number: 9988446
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: June 5, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • Patent number: 9914772
    Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: March 13, 2018
    Assignee: Cell Medica Switzerland AG
    Inventors: Annemarie Honegger, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Stefanie Grabulovski
  • Patent number: 9895420
    Abstract: The present invention provides a chimera protein made of amino acid residues derived from IL-1beta propeptide and the IL-1Ra mature peptide and polynucleotides encoding the protein. The present invention also provides usages of the protein and the polynucleotides in pharmaceutical compositions that treat inflammation.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: February 20, 2018
    Assignees: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN GURION UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Eli Lewis, Peleg Rider, Charles A. Dinarello
  • Patent number: 9890219
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: February 13, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Patent number: 9862765
    Abstract: Provided is an antibody capable of specially recognizing IL-17A and binding to IL-17A. The antibody can be used for treating inflammation and autoimmune diseases caused by elevated expression of interleukin-17A, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: January 9, 2018
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Lianshan Zhang, Jiajian Liu, Guoqing Cao, Piaoyang Sun